Prinomastat

Drug Profile

Prinomastat

Alternative Names: AG 3340; AG 3354 (hydrochloride); AG 3362 (maleate); Cytaq

Latest Information Update: 20 Nov 2002

Price : $50

At a glance

  • Originator Agouron Pharmaceuticals
  • Class Antineoplastics; Hydroxamic acids; Small molecules; Thiamorpholines
  • Mechanism of Action Angiogenesis inhibitors; Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Age-related macular degeneration; Breast cancer; Glioblastoma; Lung cancer; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 20 Nov 2002 Discontinued - Phase-II for Age-related macular degeneration in USA (PO)
  • 20 Nov 2002 Discontinued - Phase-II for Glioblastoma in USA (PO)
  • 20 Nov 2002 Discontinued - Preclinical for Breast cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top